Inozyme Pharma Inc. (INZY): Price and Financial Metrics
GET POWR RATINGS... FREE!
INZY Stock Price Chart Interactive Chart >
INZY Price/Volume Stats
|Current price||$3.97||52-week high||$19.58|
|Prev. close||$3.94||52-week low||$3.54|
|Day high||$4.08||Avg. volume||167,127|
|50-day MA||$4.26||Dividend yield||N/A|
|200-day MA||$7.84||Market Cap||159.19M|
Inozyme Pharma Inc. (INZY) Company Bio
Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
Most Popular Stories View All
INZY Latest News Stream
|Loading, please wait...|
INZY Latest Social Stream
View Full INZY Social Stream
Latest INZY News From Around the Web
Below are the latest news stories about Inozyme Pharma Inc that investors may wish to consider to help them evaluate INZY as an investment opportunity.
Who doesn’t like a bargain? In these days, with price inflation hitting hard, we all want to find the best price on every purchase – and that includes our stock purchases. Bargain-conscious investors can still find those fundamentally solid stocks that are trading low; this is the essence of successful stock investing. To make it easy, we’ve done some of the background research. We’ve located three stocks that are down 50% or more, and confirmed that these are Strong Buy stocks, that have gotten plenty of recent approval from the Street’s stock pros.
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA (OBSV – Research Report), Inozyme Pharma (INZY – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments. ObsEva SA (OBSV) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA today and set a price target of $15.00. The company's shares closed last Friday at $1.43, close to its 52-week low of $1.35. According to TipRanks.
H.C. Wainwright had initiated Inozyme Pharma with a buy based on optimism for its enzyme replacement therapy INZ-701.
Needham & Company LLC initiated coverage on shares of Inozyme Pharma (NASDAQ:INZY) in a research report report published on Monday, Analyst Ratings Network reports. The firm issued a buy rating and a $23.00 target price on the stock. Separately, Zacks Investment Research lowered shares of Inozyme Pharma from a buy rating to a hold rating 
Nuveen Asset Management LLC lifted its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) by 122.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,394 shares of the companys stock after purchasing an additional 26,102 shares during the period. Nuveen 
INZY Price Returns